Gujarat Themis Biosyn Ltd - 506879 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Gujarat Themis Biosyn shareholders approved special resolutions to increase borrowing limits and expand inter-corporate investment capabilities. Both resolutions passed with over 98% votes in favour, enabling greater financial flexibility.
Jun 05 2026 12:10:02
Gujarat Themis Biosyn Ltd - 506879 - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Gujarat Themis Biosyn shareholders approved special resolutions to increase borrowing and investment limits. This enhances the company's financial flexibility for future growth and operations.
Jun 05 2026 12:05:39
Gujarat Themis Biosyn Ltd - 506879 - Board Meeting Intimation for Consideration And Evaluate The Proposals For Raising Funds By Way Of Issue Of Equity Shares / Securities Through Qualified Institutions Placement Or Preferential Allotment Or Any Other Methods / Modes Or Combination Thereof.
Gujarat Themis Biosyn board will convene on June 6, 2026, to consider and evaluate proposals for raising funds. The fundraise may be through Qualified Institutions Placement (QIP) or preferential allotment.
Jun 03 2026 18:13:19
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn incorporated a new wholly-owned subsidiary, Themis Biosyn Ireland Private Limited, in Ireland on May 29, 2026. This strategic move aims to expand the company's pharmaceutical business into international markets.
May 29 2026 23:05:09
Gujarat Themis Biosyn Ltd - 506879 - Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Gujarat Themis Biosyn approved FY26 audited financial results, reporting a total income of ₹168.25 crore and a net profit of ₹46.68 crore. The company recommended a final dividend of ₹0.67 per equity share and approved a preferential issue of equity shares.
May 25 2026 15:07:09
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Ltd. will acquire MicroBiopharm Japan Co., Ltd. for Rs. 1,300 crore. This acquisition marks a strategic move to transform GTBL into a technology-driven Contract Development Manufacturing Organization (CDMO) platform. The deal will be completed by September 2026.
May 22 2026 21:18:08
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Ltd. (GTBL) will acquire 100% equity of Japan-based MicroBiopharm Japan Co., Ltd. (MBJ) for approximately INR 1,300 crores. This acquisition is strategic, aimed at transforming GTBL into a globally integrated CDMO platform with advanced fermentation and biotechnology capabilities.
May 22 2026 20:48:08
Gujarat Themis Biosyn Ltd - 506879 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Gujarat Themis Biosyn acquired 100% equity in MicroBiopharm Japan Co., Ltd. for Rs.1,300 crore (JPY 21.5 billion). This strategic acquisition aims to transform GTBL into a technology-driven Contract Development Manufacturing Organization (CDMO) platform by enhancing its fermentation capabilities and proprietary technologies.
May 22 2026 20:43:17
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited (GTBL) has acquired 100% equity in Japan's MicroBiopharm Japan Co., Ltd. (MBJ) for approximately INR 1,300 crores. This strategic acquisition will enable GTBL to transition into a technology-driven CDMO platform, enhancing capabilities in microbial fermentation and biotechnology-based manufacturing.
May 22 2026 20:39:46
Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited (GTBL) has acquired 100% equity in Japan's MicroBiopharm Japan Co., Ltd. (MBJ) for approximately INR 1,300 crores. This strategic acquisition will enable GTBL to transition into a technology-driven CDMO platform, enhancing capabilities in microbial fermentation and biotechnology-based manufacturing.
May 22 2026 20:39:46
Read More